Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Qilian International Holding Group Limited (BGM)
:BGM
Holding BGM?
Track your performance easily
BGM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.78 - $14.78
Previous Close$12.71
Volume74.11K
Average Volume (3M)46.26K
Market Cap
$86.36M
Enterprise Value$898.52K
Total Cash (Recent Filing)$5.37M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding7,226,480
10 Day Avg. Volume45,407
30 Day Avg. Volume46,262
Standard Deviation0.31
R-Squared0.05
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.00
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.51
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Qilian International Holding Group Limited News
PremiumCompany Announcements
BGM Group Ltd Completes Strategic Acquisition of Patriton Limited
PremiumCompany Announcements
Qilian International’s Strategic Transaction and Reorganization
PremiumCompany Announcements
Qilian International Announces Major Share Subscription DealOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.07%
Mutual Funds
― Other Institutional Investors
99.93% Public Companies and
Individual Investors
BGM FAQ
What was Qilian International Holding Group Limited’s price range in the past 12 months?
Qilian International Holding Group Limited lowest stock price was $1.77 and its highest was $14.78 in the past 12 months.
What is Qilian International Holding Group Limited’s market cap?
Qilian International Holding Group Limited’s market cap is $86.36M.
When is Qilian International Holding Group Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Qilian International Holding Group Limited’s earnings last quarter?
Qilian International Holding Group Limited released its earnings results on Feb 09, 2024. The company reported -$0.232 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.232.
Is Qilian International Holding Group Limited overvalued?
According to Wall Street analysts Qilian International Holding Group Limited’s price is currently Overvalued.
Does Qilian International Holding Group Limited pay dividends?
Qilian International Holding Group Limited does not currently pay dividends.
What is Qilian International Holding Group Limited’s EPS estimate?
Qilian International Holding Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qilian International Holding Group Limited have?
Qilian International Holding Group Limited has 7,226,480 shares outstanding.
What happened to Qilian International Holding Group Limited’s price movement after its last earnings report?
Qilian International Holding Group Limited reported an EPS of -$0.232 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.719%.
Which hedge fund is a major shareholder of Qilian International Holding Group Limited?
Currently, no hedge funds are holding shares in BGM
---
Qilian International Holding Group Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Company Description
Qilian International Holding Group Limited
Qilian International Holding Group Ltd is a pharmaceutical and chemical company. The company is engaged in the development, manufacture, marketing, and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives products, heparin products, sausage casings, and fertilizers. It operates through three segments namely, Oxytetracycline and Licoriceproducts and TCMD; Fertilizer; and Heparinproducts and Sausage casing. Oxytetracycline and Licorice products and TCMD segment generate most of the revenue.
---
Technical Analysis
---